* AZ focus on early cancer after lagging in advanced disease (Adds analyst reaction and shares)

AstraZeneca's immunotherapy drug Imfinzi cut the risk of death in patients with mid-stage lung cancer by nearly a third in a closely watched clinical study, reinforcing the case for using the drug in earlier disease.

The Swiss blue-chip SMI was seen opening little changed at 8,943 points on Tuesday, according to premarket indications by bank Julius Baer .

The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil at the behest of a presidential candidate who pushed for the move, paving the way for cheaper generics.

A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

Endo International Plc is halting its lawsuit against the U.S. Food And Drug Administration until the end of the year after the agency made new commitments on the regulation relating to the active ingredient in blood pressure medicine Vasostrict.

For three whirlwind days in June, U.S. scientist Zhi Hong went shopping at the Boston Bio Conference to find drugs to fill the pipeline of his two-week-old drug company.

Endo International Plc on Monday said it would stay its lawsuit against the U.S. Food And Drug Administration until the end of the year after the FDA made new commitments on the regulation surrounding the active ingredient in its blood pressure medicine Vasostrict.